Brain Targeting, Antioxidant Polymeric Nanoparticles for Stroke Drug Delivery and Therapy

Haoan Wu,Bin Peng,Farrah S. Mohammed,Xingchun Gao,Zhenpeng Qin,Kevin N. Sheth,Jiangbing Zhou,Zhaozhong Jiang

DOI: https://doi.org/10.1002/smll.202107126

IF: 13.3

2022-03-20

Small

Abstract:Small, EarlyView.

materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter,nanoscience & nanotechnology

What problem does this paper attempt to address?

An Ultrasmall Cu/Cu<sub>2</sub>O Nanoparticle-Based Diselenide-Bridged Nanoplatform Mediating Reactive Oxygen Species Scavenging and Neuronal Membrane Enhancement for Targeted Therapy of Ischemic Stroke

Xiaohan Ge

DOI: https://doi.org/10.1021/acsnano.3c08734

IF: 17.1

2023-01-01

ACS Nano

Abstract:Ischemic stroke is one of the major causes of death and disability worldwide, and an effective and timely treatment of ischemic stroke has been a challenge because of the narrow therapeutic window and the poor affinity with thrombus of the thrombolytic agent. In this study, rPZDCu, a multifunctional nanoparticle (NP) with the effects of thrombolysis, reactive oxygen species (ROS) scavenging, and neuroprotection, was synthesized based on an ultrasmall Cu4.6O NP, the thrombolytic agent rt-PA, and docosahexaenoic acid (DHA), which is a major component of the neuronal membrane. rPZDCu showed strong thrombus-targeting ability, which was achieved by the platelet cell membrane coating on the NP surface, and a good thrombolytic effect in both the common carotid artery clot model and embolic middle cerebral artery occlusion (MCAO) model of rats. Furthermore, rPZDCu exhibited a good escape from the phagocytosis of macrophages, effective promotion of the polarization of microglia, and efficient recovery of neurobiological and behavioral functions in the embolic MCAO model of rats. This is a heuristic report of (1) the Cu-0/Cu+ NP for the treatments of brain diseases, (2) the integration of DHA and ROS scavengers for central nervous system therapies, and (3) diselenide-based ROS-responsive NPs for ischemic stroke treatments. This study also offers an example of cell membrane-camouflaged stimuli-responsive nanomedicine for brain-targeting drug delivery.
Reactive Oxygen Species-Responsive Nanotherapy for the Prevention and Treatment of Cerebral Ischemia–reperfusion Injury

Jianglong Kong,Runxuan Chu,Junjie Wen,Hongrui Yu,Jiawen Liu,Yuting Sun,Meiru Mao,Xiaohan Ge,Zixin Jin,Weimin Huang,Na Hu,Yi Zhang,David Y. Wang,Yi Wang

DOI: https://doi.org/10.1016/j.cej.2024.153023

IF: 15.1

2024-01-01

Chemical Engineering Journal

Abstract:Vascular recanalization intervention is the primary recommended approach for the treatment of ischemic stroke. However, the damage caused by cerebral ischemia-reperfusion (I/R) poses a significant challenge for effective treatment. The aim of this study was to address this challenge by developing multifunctional nanoparticles (NPs). Cu4.6O NP was encapsulated by zein-Se-Se-DHA (Dz), the diselenide bond-conjugated zein and docosahexaenoic acid (DHA), and then coated by platelet membrane (PLTM) to form Cu4.6O@Dz@PLTM (MDzCu) NP. MDzCu with the PLTM coating showed strong targeting ability to the cerebral ischemic lesions in the rat model of cerebral I/R injury. Furthermore, in the reactive oxygen species (ROS)-rich brain microenvironment, both Cu4.6O and DHA are released from MDzCu, exerting ROS scavenging, promoting microglia polarization, and providing neuroprotective effects, ultimately alleviating cerebral I/R injury. This study presents several novel findings, such as the use of Cu0/Cu+ NPs for brain-related diseases, ROS scavenger-assisted DHA therapy for the central nervous system (CNS), and the application of stimuli-responsive NPs with diselenides to treat I/R injuries. This study provides insights into the development of stimuli-responsive nanomedicines with cell membrane coatings for the targeted treatment of brain diseases.
Brain-targeting, acid-responsive antioxidant nanoparticles for stroke treatment and drug delivery

Shenqi Zhang,Bin Peng,Zeming Chen,Jiang Yu,Gang Deng,Youmei Bao,Chao Ma,Fengyi Du,Wendy C. Sheu,W. Taylor Kimberly,J. Marc Simard,Daniel Coman,Qianxue Chen,Fahmeed Hyder,Jiangbing Zhou,Kevin N. Sheth

DOI: https://doi.org/10.1016/j.bioactmat.2022.02.033

IF: 18.9

2022-10-01

Bioactive Materials

Abstract:Highlights•Single component natural compound-derived nanoparticles functioning as antioxidants for effective stroke treatment.•An approach to engineering betulinic acid nanoparticles to respond to acidic ischemic brain environment.•An approach to engineer nanoparticles for targeted drug delivery to the ischemic brain through interaction with CXCR4.•A NA1 nanoparticle formulation enabling neuroprotection and antioxidant effects for potential clinical translationStroke is the leading cause of death and disability. Currently, there is no effective pharmacological treatment for this disease, which can be partially attributed to the inability to efficiently deliver therapeutics to the brain. Here we report the development of natural compound-derived nanoparticles (NPs), which function both as a potent therapeutic agent for stroke treatment and as an efficient carrier for drug delivery to the ischemic brain. First, we screened a collection of natural nanomaterials and identified betulinic acid (BA) as one of the most potent antioxidants for stroke treatment. Next, we engineered BA NPs for preferential drug release in acidic ischemic tissue through chemically converting BA to betulinic amine (BAM) and for targeted drug delivery through surface conjugation of AMD3100, a CXCR4 antagonist. The resulting AMD3100-conjugated BAM NPs, or A-BAM NPs, were then assessed as a therapeutic agent for stroke treatment and as a carrier for delivery of NA1, a neuroprotective peptide. We show that intravenous administration of A-BAM NPs effectively improved recovery from stroke and its efficacy was further enhanced when NA1 was encapsulated. Due to their multifunctionality and significant efficacy, we anticipate that A-BAM NPs have the potential to be translated both as a therapeutic agent and as a drug carrier to improve the treatment of stroke.Graphical abstractDownload : Download high-res image (245KB)Download : Download full-size image

engineering, biomedical,materials science, biomaterials
Dual Targeted Nanocarrier for Brain Ischemic Stroke Treatment

Yue Zhao,Yan Jiang,Wei Lv,Zhongyuan Wang,Lingyan Lv,Baoyan Wang,Xin Liu,Yang Liu,Quanyin Hu,Wujin Sun,Qunwei Xu,Hongliang Xin,Zhen Gu

DOI: https://doi.org/10.1016/j.jconrel.2016.04.038

IF: 11.467

2016-01-01

Journal of Controlled Release

Abstract:Focal cerebral ischemia, known as stroke, causes serious long-term disabilities globally. Effective therapy for cerebral ischemia demands a carrier that can penetrate the blood-brain barrier (BBB) and subsequently target the ischemia area in brain. Here, we designed a novel neuroprotectant (ZL006) loaded dual targeted nanocarrier based on liposome (T7&SHp-P-LPs/ZL006) conjugated with T7 peptide (T7) and stroke homing peptide (SHp) for penetrating BBB and targeting ischemia area, respectively. Compared with non-targeting liposomes, T7&SHp-P-LPs/ZL006 could transport across BCEC cells and significantly enhance cellular uptake and reduce cells apoptosis of excitatory amino acid stimulated PC-12 cells. However, there was no significant difference in cellular uptake between SHp-modified and plain liposomes when PC-12 cells were incubated without excitatory amino acid. Besides, ex vivo fluorescent images indicated that DiR labeled T7&SHp-P-LPs could efficiently transport across BBB and mostly accumulated in ischemic region rather than normal cerebral hemisphere of MCAO rats. Furthermore, T7&SHp-P-LPs/ZL006 could enhance the ability of in vivo anti-ischemic stroke of MCAO rats. These results demonstrated that T7&SHp-P-LPs could be used as a safe and effective dual targeted nanocarrier for ischemic stroke treatment.
Micro‐Nanocarriers Based Drug Delivery Technology for Blood‐Brain Barrier Crossing and Brain Tumor Targeting Therapy (small 45/2022)

Luyao Wang,Youyuan Shi,Jingzhen Jiang,Chan Li,Hengrui Zhang,Xinhui Zhang,Tao Jiang,Liang Wang,Yinyan Wang,Lin Feng

DOI: https://doi.org/10.1002/smll.202270241

IF: 13.3

2022-01-01

Small

Abstract:Blood–Brain Barrier Therapy The blood–brain barrier (BBB) is a bottleneck in the treatment of brain tumors. In article number 2203678, Liang Wang, Yinyan Wang, Lin Feng, and co-workers summarize the current approaches to overcome the BBB, such as the use of “Trojan horse” molecular modifications for deception, and describe a variety of micro-nanocarriers for targeted brain tumor therapy.
Hollow Prussian Blue Nanozymes Drive Neuroprotection Against Ischemic Stroke Via Attenuating Oxidative Stress, Counteracting Inflammation, and Suppressing Cell Apoptosis

Kai Zhang,Mengjiao Tu,Wei Gao,Xiaojun Cai,Fahuan Song,Zheng Chen,Qian Zhang,Jing Wang,Chentao Jin,Jingjing Shi,Xiang Yang,Yuankai Zhu,Weizhong Gu,Bing Hu,Yuanyi Zheng,Hong Zhang,Mei Tian

DOI: https://doi.org/10.1021/acs.nanolett.8b04729

IF: 10.8

2019-01-01

Nano Letters

Abstract:Ischemic stroke is a devastating disease and one of the leading causes of mortality worldwide. Overproduction of reactive oxygen and nitrogen species (RONS) following ischemic insult is known as a key factor in exacerbating brain damage. Thus, RONS scavengers that can block excessive production of RONS have great therapeutic potential. Herein, we propose an efficient treatment strategy in which an artificial nanozyme with multienzyme activity drives neuroprotection against ischemic stroke primarily by scavenging RONS. Specifically, through a facile, Bi3+-assisted, template-free synthetic strategy, we developed hollow Prussian blue nanozymes (HPBZs) with multienzyme activity to scavenge RONS in a rat model of ischemic stroke. The comprehensive characteristics of HPBZs against RONS were explored. Apart from attenuating oxidative stress, HPBZs also suppressed apoptosis and counteracted inflammation both in vitro and in vivo, thereby contributing to increased brain tolerance of ischemic injury with minimal side effects. This study provides a proof of concept for a novel class of neuroprotective nanoagents that might be beneficial for treatment of ischemic stroke and other RONS-related disorders.
Targeted pathophysiological treatment of ischemic stroke using nanoparticle-based drug delivery system

Wei Liu,Lubin Liu,Hong Li,Yutong Xie,Ju Bai,Jialiang Guan,Hongzhao Qi and Jinping Sun

DOI: https://doi.org/10.1186/s12951-024-02772-2

IF: 10.2

2024-08-23

Journal of Nanobiotechnology

Abstract:Ischemic stroke poses significant challenges in terms of mortality and disability rates globally. A key obstacle to the successful treatment of ischemic stroke lies in the limited efficacy of administering therapeutic agents. Leveraging the unique properties of nanoparticles for brain targeting and crossing the blood–brain barrier, researchers have engineered diverse nanoparticle-based drug delivery systems to improve the therapeutic outcomes of ischemic stroke. This review provides a concise overview of the pathophysiological mechanisms implicated in ischemic stroke, encompassing oxidative stress, glutamate excitotoxicity, neuroinflammation, and cell death, to elucidate potential targets for nanoparticle-based drug delivery systems. Furthermore, the review outlines the classification of nanoparticle-based drug delivery systems according to these distinct physiological processes. This categorization aids in identifying the attributes and commonalities of nanoparticles that target specific pathophysiological pathways in ischemic stroke, thereby facilitating the advancement of nanomedicine development. The review discusses the potential benefits and existing challenges associated with employing nanoparticles in the treatment of ischemic stroke, offering new perspectives on designing efficacious nanoparticles to enhance ischemic stroke treatment outcomes.

biotechnology & applied microbiology,nanoscience & nanotechnology
Advances in nanoparticle-based therapeutics for ischemic stroke: Enhancing drug delivery and efficacy

Peng Ji,Qingqing Xu,Jiahui Li,Zihan Wang,Wanyi Mao,Peng Yan

DOI: https://doi.org/10.1016/j.biopha.2024.117564

IF: 7.419

2024-10-15

Biomedicine & Pharmacotherapy

Abstract:Ischemic stroke, characterized by vascular occlusion, has recently emerged as one of the primary causes of mortality and disability worldwide. Conventional treatment modalities, such as thrombolytic and neuroprotective therapies, face numerous challenges, including limited bioavailability, significant neurotoxicity, suboptimal targeting, short half-life, and poor blood-brain barrier (BBB) penetration. Nanoparticle-based drug delivery systems present distinct advantages, such as small size, enhanced lipophilicity, and modifiability, which can potentially address these limitations. Utilizing nanoparticles for drug delivery in ischemic stroke therapy offers improved drug bioavailability, reduced neurotoxicity, enhanced targeted delivery, prolonged drug half-life, and better dissolution kinetics. This review aims to provide a comprehensive overview of current strategies in preclinical studies for managing or preventing ischemic stroke from a nanomaterial perspective, highlighting the advantages and limitations of each approach.

pharmacology & pharmacy,medicine, research & experimental
Targeted Therapy of Ischemic Stroke Via Crossing the Blood-Brain Barrier Using Edaravone-Loaded Multiresponsive Microgels.

Hongwei Lin,Yi Zhang,Shunni Dong,Xiaobo Cai,Hui Jiang,Yang Fan,Kaiyue Ying,Binyang Du,Peilin Yu,Wei Yang

DOI: https://doi.org/10.1021/acsabm.2c00325

2022-01-01

ACS Applied Bio Materials

Abstract:Ischemic stroke, as a prevalent neurological disorder, often results in rapid increases in the production of reactive oxygen species (ROS) and inflammatory factors in the focal ischemic area. Though edaravone is an approved treatment, its effect is limited due to its weak ability to cross the blood-brain barrier (BBB) and short half-life. Other effective pharmacological treatment options are clearly lacking. In this study, PNIVDBrF-3-Eda (also named MG-3-Eda) was prepared using a thermo- and pH dual-responsive PNIVDBrF microgel. These were designed with a positively charged network, as synthesized by simultaneous quaternization cross-linking and surfactant-free emulsion copolymerization, to be loaded with the negatively charged edaravone. We then investigated whether such a targeted delivery of edaravone could provide enhanced neuroprotection. Cytotoxicity assays confirmed that the microgel (<1 mg/mL) exhibited promising cytocompatibility with no remarkable effect on cell viability, cell cycle regulation, or apoptosis levels. In vitro and in vivo experiments demonstrated that the microgels could successfully penetrate the blood-brain barrier where efficient BBB crossing was observed after disruption of the BBB due to ischemic injury. This enabled MG-3-Eda to target the cerebral ischemic area and achieve local release of edaravone. Treatment with MG-3-Eda significantly reduced the cerebral infarct area in transient middle cerebral artery occlusion (tMCAO) mice and significantly improved behavioral scores. MG-3-Eda treatment also prevented the reduction in NF200 expression, a neuronal marker protein, and attenuated microglia activation (as detected by Iba1) in the local ischemic area via local antioxidant and anti-inflammatory effects. A superior neuroprotective effect was noted for MG-3-Eda compared to that for free edaravone. Our results indicate that MG-3-Eda administration represents a clear potential treatment for cerebral ischemia via its targeted delivery of edaravone to ischemic areas where it provides significant local antioxidant and anti-inflammatory effects.
Pathogenesis-adaptive Polydopamine Nanosystem for Sequential Therapy of Ischemic Stroke

Di Wu,Jing Zhou,Yanrong Zheng,Yuyi Zheng,Qi Zhang,Zhuchen Zhou,Xiaojie Chen,Qi Chen,Yeping Ruan,Yi Wang,Zhong Chen

DOI: https://doi.org/10.1038/s41467-023-43070-z

IF: 16.6

2023-01-01

Nature Communications

Abstract:Ischemic stroke is lethal cerebrovascular disease, and reperfusion as the main strategy of blood supply restoration can cause severe ischemic brain damage. Considered as the major obstacle in medication for stroke, neuroinflammation after reperfusion undergoes dynamic progression, making precision treatment for stroke a Herculean task. In this work, we report a pathogenesis-adaptive polydopamine nanosystem for sequential therapy of ischemic stroke. Intrinsic free radical scavenging and tailored mesostructure of the nanosystem can attenuate oxidative stress at the initial stage. Upon microglial overactivation at the later stage, minocycline-loaded nanosystem can timely reverse the pro-inflammatory transition in response to activated matrix metalloproteinase-2, providing on-demand regulation. Further in vivo stroke study demonstrates a higher survival rate and improved brain recovery of the sequential strategy, compared with mono-therapy and combined therapy. Complemented with satisfactory biosafety results, this adaptive nanosystem for sequential and on-demand regulation of post-stroke neuroinflammation is a promising approach to ischemic stroke therapy.
Brain targeted polymeric micelles as drug carriers for ischaemic stroke treatment

Zirui Zhao,Huijia Song,Mengge Qi,Yurong Liu,Yanchao Zhang,Shuo Li,Huimin Zhang,Yongjun Sun,Yanping Sun,Zibin Gao

DOI: https://doi.org/10.1080/1061186x.2024.2417190

2024-10-20

Journal of Drug Targeting

Abstract:Ischaemic stroke is a central nervous system disease with high morbidity, recurrence and mortality rates. Thrombolytic and neuroprotective therapies are the main therapeutic strategies for ischaemic stroke, however, the poor delivery efficiency of thrombolytic and neuroprotective drugs to the brain limits their clinical application. So far, the development of nanomedicine has brought opportunities for the above challenges, which can not only realise the effective accumulation of drugs in the target site, but also improve the pharmacokinetic behaviour of the drugs. Among the most rapidly developing nanoparticles, micelles gradually emerging as an effective strategy for ischaemic stroke treatment due to their own unique advantages. This review provided an overview of targeted and response-release micelles based on the physicochemical properties of the ischaemic stroke microenvironment, summarised the targeting strategies for delivering micellar formulations to the thrombus, blood-brain barrier, and brain parenchyma, and finally described the potentials and challenges of polymeric micelles in the treatment of ischaemic stroke.

pharmacology & pharmacy
Ultrasmall Iron‐gallic Acid Coordination Polymer Nanodots with Antioxidative Neuroprotection for PET/MR Imaging‐guided Ischemia Stroke Therapy

Yujing Du,Yan Huo,Qi Yang,Zhihui Han,Linqian Hou,Bixiao Cui,Kevin Fan,Yongkang Qiu,Zhao Chen,Wenpeng Huang,Jie Lu,Liang Cheng,Weibo Cai,Lei Kang

DOI: https://doi.org/10.1002/exp.20220041

2023-01-01

Abstract:Oxidative stress from reactive oxygen species (ROS) is a reperfusion injury factor that can lead to cell damage and death. Here, ultrasmall iron-gallic acid coordination polymer nanodots (Fe-GA CPNs) were developed as antioxidative neuroprotectors for ischemia stroke therapy guided by PET/MR imaging. As proven by the electron spin resonance spectrum, the ultrasmall Fe-GA CPNs with ultrasmall size, scavenged ROS efficiently. In vitro experiments revealed that Fe-GA CPNs could protect cell viability after being treated with hydrogen peroxide (H2O2) and displayed the effective elimination of ROS by Fe-GA CPNs, which subsequently restores oxidation balance. When analyzing the middle cerebral artery occlusion model, the neurologic damage displayed by PET/MR imaging revealed a distinct recovery after treatment with Fe-GA CPNs, which was proved by 2,3,5-triphenyl tetrazolium chloride staining. Furthermore, immunohistochemistry staining indicated that Fe-GA CPNs inhibited apoptosis through protein kinase B (Akt) restoration, whereas western blot and immunofluorescence indicated the activation of the nuclear factor erythroid 2-related factor 2 (Nrf2) and heme oxygenase-1 (HO-1) pathway following Fe-GA CPNs application. Therefore, Fe-GA CPNs exhibit an impressive antioxidative and neuroprotective role via redox homeostasis recovery by Akt and Nrf2/HO-1 pathway activation, revealing its potential for clinical ischemia stroke treatment.
Targeted Delivery of Nano-Therapeutics for Major Disorders of the Central Nervous System

Huile Gao,Zhiqing Pang,Xinguo Jiang

DOI: https://doi.org/10.1007/s11095-013-1122-4

IF: 4.58

2013-01-01

Pharmaceutical Research

Abstract:Major central nervous system (CNS) disorders, including brain tumors, Alzheimer’s disease, Parkinson’s disease, and stroke, are significant threats to human health. Although impressive advances in the treatment of CNS disorders have been made during the past few decades, the success rates are still moderate if not poor. The blood–brain barrier (BBB) hampers the access of systemically administered drugs to the brain. The development of nanotechnology provides powerful tools to deliver therapeutics to target sites. Anchoring them with specific ligands can endow the nano-therapeutics with the appropriate properties to circumvent the BBB. In this review, the potential nanotechnology-based targeted drug delivery strategies for different CNS disorders are described. The limitations and future directions of brain-targeted delivery systems are also discussed.
Nanoparticles-mediated Emerging Approaches for Effective Treatment of Ischemic Stroke.

Wenxiu He,Zhiwen Zhang,Xianyi Sha

DOI: https://doi.org/10.1016/j.biomaterials.2021.121111

IF: 14

2021-01-01

Biomaterials

Abstract:Ischemic stroke leads to high disability and mortality. The limited delivery efficiency of most therapeutic substances is a major challenge for effective treatment of ischemic stroke. Inspired by the prominent merit of nanoscale particles in brain targeting and blood-brain barrier (BBB) penetration, various functional nanoparticles have been designed as promising drug delivery platforms that are expected to improve the therapeutic effect of ischemic stroke. Based on the complex pathological mechanisms of ischemic stroke, this review outline and summarize the rationally designed nanoparticles-mediated emerging approaches for effective treatment of ischemic stroke, including recanalization therapy, neuroprotection therapy, and combination therapy. On this bases, the potentials and challenges of nanoparticles in the treatment of ischemic stroke are revealed, and new thoughts and perspectives are proposed for the design of feasible nanoparticles for effective treatment of ischemic stroke.
Polydopamine-Cloaked Nanoarchitectonics of Prussian Blue Nanoparticles Promote Functional Recovery in Neonatal and Adult Ischemic Stroke Models

Yijing Zhao,Cong Song,Haijun Wang,Chengcheng Gai,Tingting Li,Yahong Cheng,Junjie Liu,Yan Song,Qian Luo,Bing Gu,Weiyang Liu,Liwei Chai,Dexiang Liu,Zhen Wang

DOI: https://doi.org/10.34133/bmr.0079

2024-09-18

Abstract:Ischemic stroke is a devastating disease and one of the leading causes of mortality worldwide. Overproduction of reactive oxygen species and inflammatory response contribute to secondary damage following ischemic insult. Nanozymes with robust anti-oxidative stress properties possess therapeutic possibility for ischemic insult. However, insufficiency of nanozyme accumulation in the neuronal mitochondria hindered their application. Herein, we constructed polydopamine-coated Prussian blue nanoparticles (PB@PDA NPs) to realize the targeting neuronal mitochondria for ischemic stroke, with the properties of antioxidant and anti-inflammation. After administration, much higher accumulation of PB@PDA NPs in the brain was observed compared to that in the PB NP group. Moreover, PB@PDA NPs effectively attenuated brain infarct than that of PB NPs in neonatal mice following hypoxia-ischemia (HI) insult. PB@PDA NPs mainly colocated with neuronal mitochondria in vivo and in vitro. Apart from attenuating oxidative stress, PB@PDA NPs also suppressed neuronal apoptosis and counteracted inflammation, which effectively promote a short- and long-term functional recovery in HI mice. Further, the therapeutic efficacy of PB@PDA NPs was also found in adult ischemic mice via tail vein injection. Collectively, these findings illustrate that PB@PDA NPs via system injection accumulate in neuronal mitochondria and are beneficial for ischemic stroke.
Advanced nano drug delivery systems for neuroprotection against ischemic stroke

Chenchen Xie,Jun Liao,Ning Zhang,Yuhan Sun,Yi Li,Liyan Xiong,Yingnan Zhang,Xiaoyan Liu,Wei Su,Heming Chen,Ping Zeng,Xiaoqing Zhang,Ying Lu,Tingfang Wang,Chuan Zhang

DOI: https://doi.org/10.1016/j.cclet.2023.109149

IF: 9.1

2023-09-01

Chinese Chemical Letters

Abstract:Ischemic stroke (IS) represents a significant threat to brain health due to its elevated mortality and disability rates. The efficacy of small-molecule neuroprotective agents has been impeded by challenges associated with traversing the blood-brain barrier (BBB) and limited bioavailability. Conversely, advanced nano drug delivery systems hold promise for overcoming these obstacles by facilitating efficient transportation across the BBB and maintaining optimal drug concentrations. This review aims to explore advanced neuroprotective nano drug delivery systems as a means of effectively administering neuroprotective agents to the brain using pharmaceutical approaches in the treatment of IS. By examining these systems, researchers and clinicians can gain valuable insights and innovative concepts, illuminating the potential of advanced neuroprotective nano drug delivery systems. Leveraging these advancements can drive the progress of pioneering and efficacious therapeutic interventions for IS.

chemistry, multidisciplinary
Salvaging Brain Ischemia by Increasing Neuroprotectant Uptake Via Nanoagonist Mediated Blood Brain Barrier Permeability Enhancement

Shuyan Zheng,Ying-Ying Bai,Yikang Liu,Xihui Gao,Yan Li,Yinzhi Changyi,Yuancheng Wang,Di Chang,Shenghong Ju,Cong Li

DOI: https://doi.org/10.1016/j.biomaterials.2015.07.006

IF: 14

2015-01-01

Biomaterials

Abstract:Ischemic stroke is a leading cause of adult disability and cognitive impairment worldwide. Neuroprotective therapy aims to save neurons by impeding the deleterious ischemic insults. However, the low efficiency of the neuroprotectants crossing blood brain barrier (BBB) prevents their clinical translation. In this work, a nanoagonist (NA) was developed to enhance neuroprotectant uptake by specifically increasing BBB permeability in brain ischemia. This NA first targeted ischemic brain vasculatures, temporarily opened local BBB by activating adenosine 2A receptors, and up-regulated the neuroprotectant uptake in brain ischemia. This NA significantly increased the delivery of superoxide dismutase (SOD), a free radical scavenger, into mouse brain ischemia. The combined treatment of NA/SOD achieved a five-fold ischemic volume reduction rate compared to the animal models treated with SOD alone. Non-invasive magnetic resonance imaging (MRI) confirmed the ischemia targeted BBB opening, increased brain drug delivery efficiency and up-regulated therapeutic response during the combined NA/SOD treatment. Since the inefficient brain drug delivery is a general problem for the treatment of central nervous system (CNS) diseases, this work provides a novel strategy to deliver therapeutics by crossing BBB with high efficiency and targeting specificity.
Targeted Delivery of Β-Carotene Potentially Prevents Blood-Brain Barrier Breakdown after Stroke in Mice

Qaisar Mahmood,Nan-Nan Lu,Xiao-Juan Wang,Yong-Zhong Du,Muhammad Usman Ghori,Bing Tian,Hong-Yu Yang,Feng Han,Guo-Jun Jiang,Ying-mei Lu

DOI: https://doi.org/10.1016/j.phyplu.2023.100426

2023-01-01

Phytomedicine Plus

Abstract:•Nitrosative stress caused BBB breakdown during brain ischemia.•3-NT/LNPs carrier system efficiently delivers β-carotene at the site of ischemia.•Inhibition of ONOO- prevents ischemia-reperfusion injury.
Nanotechnology approaches to drug delivery for the treatment of ischemic stroke

Bin Peng,Farrah S. Mohammed,Xiangjun Tang,Jia Liu,Kevin N. Sheth,Jiangbing Zhou

DOI: https://doi.org/10.1016/j.bioactmat.2024.09.016

IF: 18.9

2024-09-25

Bioactive Materials

Abstract:Highlights • Ischemic stroke is a major global public health concern with no effective treatment options. • Inadequate drug delivery represents a significant hurdle for the clinical translation of pharmacological therapies. • Nanotechnology presents a promising approach to overcoming this drug delivery challenge. Ischemic stroke is a major global public health concern that lacks effective treatment options. A significant challenge lies in delivering therapeutic agents to the brain due to the restrictive nature of the blood-brain barrier (BBB). The BBB's selectivity hampers the delivery of therapeutically relevant quantities of agents to the brain, resulting in a lack of FDA-approved pharmacotherapies for stroke. In this article, we review therapeutic agents that have been evaluated in clinical trials or are currently undergoing clinical trials. Subsequently, we survey strategies for synthesizing and engineering nanoparticles (NPs) for drug delivery to the ischemic brain. We then provide insights into the potential clinical translation of nanomedicine, offering a perspective on its transformative role in advancing stroke treatment strategies. In summary, existing literature suggests that drug delivery represents a major barrier for clinical translation of stroke pharmacotherapies. While nanotechnology has shown significant promise in addressing this challenge, further advancements aimed at improving delivery efficiency and simplifying formulations are necessary for successful clinical translation. Graphical abstract Download: Download high-res image (263KB) Download: Download full-size image

engineering, biomedical,materials science, biomaterials
Application of Nanotechnology-Based Products in Stroke

Cai Wang,Jingyi Sun,Qian Chen,Jixiang Chen,Huiyu Wan,Qingbin Ni,Hui Yuan,Jingguo Wu,Ying Wang,Baoliang Sun

DOI: https://doi.org/10.1021/acschemneuro.2c00804

2023-07-05

Abstract:Stroke is a disease with high disability and high mortality in the world. Due to the existence of the blood-brain barrier (BBB), complex brain structure, and numerous neural signal pathways, the treatment methods are limited, so new drugs and new treatments need to be developed urgently. Thankfully, the advent of nanotechnology offered a new opportunity for biomedical development because of the unique properties of nanoparticles that give them the ability to traverse the BBB and accumulate in relevant regions of the brain. More importantly, nanoparticles could be modified on the surface to meet a variety of specific properties that people need. Some could be used for effective drug delivery, including tissue plasminogen activator (tPA), neuroprotective agents, genes, and cytokines; some nanoparticles were used as contrast agents and biosensors in medical imaging for further diagnosis of stroke; some were used to track target cells for prognosis of stroke; and some were used to detect pathological markers of stroke that appear at different stages. This Review looks at the application and research progress of nanoparticles in the diagnosis and treatment of stroke, hoping to bring some help to researchers.

Brain Targeting, Antioxidant Polymeric Nanoparticles for Stroke Drug Delivery and Therapy

An Ultrasmall Cu/Cu<sub>2</sub>O Nanoparticle-Based Diselenide-Bridged Nanoplatform Mediating Reactive Oxygen Species Scavenging and Neuronal Membrane Enhancement for Targeted Therapy of Ischemic Stroke

Reactive Oxygen Species-Responsive Nanotherapy for the Prevention and Treatment of Cerebral Ischemia–reperfusion Injury

Brain-targeting, acid-responsive antioxidant nanoparticles for stroke treatment and drug delivery

Dual Targeted Nanocarrier for Brain Ischemic Stroke Treatment

Micro‐Nanocarriers Based Drug Delivery Technology for Blood‐Brain Barrier Crossing and Brain Tumor Targeting Therapy (small 45/2022)

Hollow Prussian Blue Nanozymes Drive Neuroprotection Against Ischemic Stroke Via Attenuating Oxidative Stress, Counteracting Inflammation, and Suppressing Cell Apoptosis

Targeted pathophysiological treatment of ischemic stroke using nanoparticle-based drug delivery system

Advances in nanoparticle-based therapeutics for ischemic stroke: Enhancing drug delivery and efficacy

Targeted Therapy of Ischemic Stroke Via Crossing the Blood-Brain Barrier Using Edaravone-Loaded Multiresponsive Microgels.

Pathogenesis-adaptive Polydopamine Nanosystem for Sequential Therapy of Ischemic Stroke

Brain targeted polymeric micelles as drug carriers for ischaemic stroke treatment

Ultrasmall Iron‐gallic Acid Coordination Polymer Nanodots with Antioxidative Neuroprotection for PET/MR Imaging‐guided Ischemia Stroke Therapy

Targeted Delivery of Nano-Therapeutics for Major Disorders of the Central Nervous System

Nanoparticles-mediated Emerging Approaches for Effective Treatment of Ischemic Stroke.

Polydopamine-Cloaked Nanoarchitectonics of Prussian Blue Nanoparticles Promote Functional Recovery in Neonatal and Adult Ischemic Stroke Models

Advanced nano drug delivery systems for neuroprotection against ischemic stroke

Salvaging Brain Ischemia by Increasing Neuroprotectant Uptake Via Nanoagonist Mediated Blood Brain Barrier Permeability Enhancement

Targeted Delivery of Β-Carotene Potentially Prevents Blood-Brain Barrier Breakdown after Stroke in Mice

Nanotechnology approaches to drug delivery for the treatment of ischemic stroke

Application of Nanotechnology-Based Products in Stroke